Premium
Strategies of Combination Drug Delivery for Immune Checkpoint Blockades
Author(s) -
Ruan Huitong,
Bu Linlin,
Hu Quanyin,
Cheng Hao,
Lu Weiyue,
Gu Zhen
Publication year - 2019
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201801099
Subject(s) - immune system , immune checkpoint , cytotoxic t cell , immunotherapy , antigen , cancer , cancer research , medicine , immunology , biology , in vitro , biochemistry
Abstract The past few years have witnessed vast clinical accomplishments of immune checkpoint blockades (ICB), which block the regulatory receptor expressed on immune cells or tumor cells to prevent the suppression of antitumor cytotoxic T‐cell responses. Despite this, limitations still exist, such as low objective response rate (ORR) and the risk of immune‐related side effects. To address these issues, combination treatment strategies are vastly explored and recommended. This review summarizes recent advances in combination of ICB with therapies that participate in different stages of cancer immune cycle, including tumor antigen release, tumor antigen presentation, T‐cell activation, recognition of cancer cells by T‐cells, and tumor‐killing activity. Challenges and potential opportunities of combination approaches in this field are also discussed.